BMS-791325
Drug timelines are a Plus or Pro feature.
16 regulatory and trial events tracked for BMS-791325, covering 2014-05-06 to 2019-08-16. Get the full timeline:
Most recent: Clinical Trial Update: A Phase 3 Study of a Daclatasvir/Asunaprevir/BMS-791325 Fixed Dose Combination (FDC) in Subjects With Chronic Hepatitis C Genotype 1 [Phase 3]